Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
Open Access
- 1 August 1980
- Vol. 21 (8) , 706-710
- https://doi.org/10.1136/gut.21.8.706
Abstract
One hundred and eighty-five patients with ulcerative colitis have been studied serially while receiving regular maintenance treatment with sulphasalazine (SASP) in a dose of 0.5 g four times daily. The circulating levels of the drug and its principal metabolites during remission do not influence the liability to relapse. When relapse does occur, the circulating level of sulphapyridine falls and remains depressed until remission occurs. This fall during a relapse is most pronounced when the patient suffers from universal colitis and is least marked in cases of distal colitis.Keywords
This publication has 7 references indexed in Scilit:
- The metabolism of salicylazosulphapyridine in ulcerative colitis: I The relationship between metabolites and the response to treatment in inpatientsGut, 1973
- Determination of salicylazosulphapyridine in biological materials.1973
- Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.1973
- Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.1973
- Absorption, metabolism, and excretion of salicylazosulfapyridine in manClinical Pharmacology & Therapeutics, 1972
- An improved and simplified method of detecting the acetylator phenotype.Journal of Medical Genetics, 1969
- Biopsy Studies in Ulcerative ColitisBMJ, 1956